Sanofi India (Large Cap) Share Target 2024, 2025 To 2039
|
Sanofi India Limited |
|||
|
Price: ₹6,162.00 | ||
| 52 Week Low: ₹5,892.80 52 Week High: ₹10,524.95 |
|||
| Market Capital: 20,379.2 Crore (Largecap) | |||
| Healthcare -> Drug Manufacturers - General | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Sanofi India Share Price Target For 2024
- 1.1.1: Sanofi India Share Price Target Table For 2024
- 1.1.2: Short-Term Technical Outlook
- 1.2: Sanofi India Share Price Target For 2025
- 1.2.1: Sanofi India Share Price Target Table For 2025
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Sanofi India Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
- 3: Sanofi India Brief Company Overview
- 4: Sanofi India Financial Performance
- 4.0.1: Is Sanofi India A Good Buy For Long Term?
To predict the Sanofi India's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Sanofi India Share Price Target For 2024
The line chart displays the monthly closing prices of Sanofi India with a black line. The green line shows three potential target prices for 2024, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Sanofi India shares in 2024, see the table below.
Sanofi India Share Price Target Table For 2024
| Level | Value | Analysis |
|---|---|---|
| 2024 Target 3 | 6415.0 (+4.10%) | Price Action: 24 Oct 2024 Low |
| 2024 Target 2 | 6336.04 (+2.82%) | Price Action: 25 Oct 2024 Low |
| 2024 Target 1 | 6267.33 (+1.70%) | Price Action: Feb 2022 Low |
| Current Price | 6162.00 | Sanofi India's share price as of 20 Dec 2024 |
| Stop Loss 1 | 6172.0 (+0.16%) | Price Action: 11 Dec 2024 Low |
| Stop Loss 2 | 6099.0 (-1.03%) | Price Action: 14 Nov 2024 Low |
| Stop Loss 3 | 6036.04 (-2.05%) | Price Action: 25 Nov 2024 Low |
Short-Term Technical Outlook
Current Technical Position: Sanofi India is displaying bearish momentum trading below key moving averages.
Key Technical Level: The 25-day moving average at ₹6209.46 serves as the nearest technical reference point.
Historical Returns: 3-month: -12.58% | 6-month: -5.20% | 1-year: -22.12%
Sanofi India Share Price Target For 2025
The line chart displays the monthly closing prices of Sanofi India with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Sanofi India shares in 2025, see the table below.
Sanofi India Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 9477.63 (+53.80%) | Price Action: Chart |
| 2025 Target 2 | 9300.91 (+50.93%) | Price Action: Chart |
| 2025 Target 1 | 9208.82 (+49.44%) | Fibonacci Extension Level 64.90% |
| Current Price | 6162.00 | Sanofi India's share price as of 20 Dec 2024 |
| Stop Loss 1 | 5473.67 (-11.18%) | Price Action: Sep 2022 Low |
| Stop Loss 2 | 5373.05 (-12.81%) | Price Action: Dec 2022 Low |
| Stop Loss 3 | 5295.96 (-14.06%) | Price Action: May 2023 Low |
Long-Term Technical Outlook
52-Week Range Analysis: Sanofi India is currently trading near its 52-week low of ₹5892.8, indicating potential value opportunity.
Long-Term Trend Analysis: The stock is in a bearish long-term trend, trading below key long-term moving averages.
Long-Term Performance: 1-year: -22.12% | 3-year: -11.88% | 5-year: +8.69%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Sanofi India Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹6,162.00 | ||
| 2024 | ₹6,220.34 | +0.95% | ₹6,337.10 |
| 2025 | ₹5,427.85 | -12.74% | ₹6,363.63 |
| 2026 | ₹4,468.68 | -17.67% | ₹5,290.48 |
| 2027 | ₹4,593.84 | +2.80% | ₹4,662.75 |
| 2028 | ₹4,843.45 | +5.43% | ₹4,916.10 |
| 2029 | ₹4,868.35 | +0.51% | ₹4,941.38 |
| 2030 | ₹6,106.31 | +25.43% | ₹6,266.74 |
| 2031 | ₹5,881.11 | -3.69% | ₹6,232.45 |
| 2032 | ₹5,875.35 | -0.10% | ₹6,031.15 |
| 2033 | ₹5,754.28 | -2.06% | ₹5,855.70 |
| 2034 | ₹5,238.39 | -8.97% | ₹5,705.50 |
| 2035 | ₹5,183.48 | -1.05% | ₹5,515.19 |
| 2036 | ₹4,964.61 | -4.22% | ₹5,276.10 |
| 2037 | ₹4,930.29 | -0.69% | ₹5,088.82 |
| 2038 | ₹4,797.92 | -2.68% | ₹4,911.27 |
| 2039 | ₹4,754.62 | -0.90% | ₹4,825.94 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Sanofi India Brief Company Overview
Sanofi India Limited: A Leading Pharmaceutical Powerhouse Established in 1956, Sanofi India Limited is a renowned manufacturer and distributor of drugs and pharmaceutical products, operating not only in India and Singapore but also internationally. Key Products and...
Services: Pharmaceutical products for therapeutic areas such as diabetes, cardiology, epilepsy, and more Exports its products globally Industry Reputation: Sanofi India Limited has a strong reputation in the pharmaceutical industry, with its products being widely recognized under trusted brands like Lantus, Toujeo, and Combiflam. Diverse Product Range: The company boasts a diverse product range, catering to a wide variety of healthcare needs, including antihistamines, vitamins, and supplements. Commitment: Sanofi India Limited is committed to providing high-quality healthcare products to patients, as evidenced by its robust distribution network and strong relationships with independent distributors.Sanofi India Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 20,379.2 Crore | Market valuation of Sanofi India's shares. |
| Revenue (TTM) | 2,846.99 Crore | Total revenue generated by Sanofi India over the past twelve months. |
| Net Income (TTM) | +5,490,999,808.00 | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +28.52% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +19.28% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
-0.60% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
-28.30% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
1.87 | Company's total debt divided by total shareholder equity. |
| Total Debt | 19 Crore | Sum of Sanofi India's current & long-term financial obligations. |
| Total Cash | 406.49 Crore | Total amount of liquid funds available to Sanofi India. |
| Beta | 0.33 | Beta is less than 1 indicating that the Sanofi India's price is less volatile than the market. |
Is Sanofi India A Good Buy For Long Term?
Sanofi India's financial performance indicates a stable revenue stream but a decline in earnings compared to the previous year. Despite prudent debt management, the low profit margin may raise concerns. While the stock has shown positive returns in the past 1 year and 5 years, its current valuation and growth prospects suggest it may not be an optimal long-term investment option.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
